+ Watch CNDO
on My Watchlist
Biotech gamble, down but not out
High risk, higher reward
Nice entry on nice little biotech with a solid pipeline and solid cash position.
Biotech. Big losses. Selling tons of stock.
The company has a smart and experienced executive team with past pharma experiencing getting drugs from the trial to FDA approved stage. It's all a question of if their innovative solutions work as they're supposed to.
This company represents a real opportunity to revolutionize the treatment of auto-immune disorders. A true paradigm shift. One of the best risk reward opportunities EVER. The opportunity is enhanced by the substantial lack of due diligence by the professional and lay community in researching the substantial research to date. This failure to investigate and understand the technology is due to the novelty of the biologic involved (porcine whipworm egg (ie;helminthic) therapy.
This young biotech has a top-notch management team and an exciting roster of drugs entering final stage testing. The drugs are targeting autoimmune diseases and cancer. The most novel is an approach using parasites to activate the immune system. Has potential to be a big winner - buy now while it's still cheap!
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions